CoChat

HDAC inhibitors and immunotherapy; a double edged sword?

Open access
Kroesen, Michiel, Gielen, Paul R., Brok, Ingrid C., Armandari, Inna, Hoogerbrugge, Peter M., Adema, Gosse J. · 2014 · Oncotarget
Cited by 166

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

// Michiel Kroesen 1,2 , Paul R. Gielen 1,* , Ingrid C. Brok 1,* , Inna Armandari 1 , Peter M. Hoogerbrugge 2,3 and Gosse J. Adema 1 1 Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands 2 Department of Pediatric Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands 3 Princes Máxima Center for Pediatric Oncology, The Bilt, The Netherlands * These authors contributed equally to this work Correspondence: Gosse J. Adema, email: // Keywords : HDAC inhibitor, cancer, immunotherapy, immunocombination therapy Received : June 27, 2014 Accepted : July 31, 2014 Published : July 31, 2014 Abstract Epigenetic modifications, like histone acetylation, are essential for regulating gene expression within cells. Cancer cells acquire pathological epigenetic modifications resulting in gene expression patterns that facilitate and sustain tumorigenesis. Epigenetic manipulation therefore is emerging as a novel targeted therapy for cancer. Histone Acetylases (HATs) and Histone Deacetylases (HDACs) regulate histone acetylation and hence gene expression. Histone deacetylase (HDAC) inhibitors are well known to affect cancer cell viability and biology and are already in use for the treatment of cancer patients. Immunotherapy can lead to clinical benefit in selected cancer patients, especially in patients with limited disease after tumor debulking. HDAC inhibitors can potentially synergize with immunotherapy by elimination of tumor cells. The direct effects of HDAC inhibitors on immune cell function, however, remain largely unexplored. Initial data have suggested HDAC inhibitors to be predominantly immunosuppressive, but more recent reports have challenged this view. In this review we will discuss the effects of HDAC inhibitors on tumor cells and different immune cell subsets, synergistic interactions and possible mechanisms. Finally, we will address future challenges and potential application of HDAC inhibitors in immunocombination therapy of cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.2289

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

Metadata

Authors
Kroesen, M., Gielen, P. R., Brok, I. C., Armandari, I., Hoogerbrugge, P. M., & Adema, G. J.
Venue
Oncotarget
Published
2014-07-31
Volume
5
Issue
16
Pages
6558-6572
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1516453481
Cited by
166
References
17
FWCI
5.72
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.